On September 2, 2025, 4D Molecular Therapeutics announced a significant expansion of its senior leadership team, appointing Dr. Julie Clark as its new Chief Medical Officer. This appointment aligns with the company's intensified focus on late-stage clinical trial and Biologics License Application (BLA) execution, as well as commercial readiness for its lead candidate, 4D-150.
Dr. Clark brings a proven track record, having led multiple BLA submissions and executed ten BLA-enabling and six Phase 3 trials for therapeutics in wet AMD and geographic atrophy. Her deep clinical and regulatory expertise is expected to be a tremendous asset as 4DMT accelerates its Phase 3 program in wet AMD and prepares for potential market entry.
The company also announced the addition of senior retina leadership advisors to further support its late-stage strategy. With this strengthened leadership, 4DMT confirmed that its 4FRONT-1 Phase 3 clinical trial for wet AMD remains on track to complete enrollment in the first quarter of 2026, moving closer to bringing 4D-150 to patients in need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.